星空体育官方入口网站网址大全-登录入口官网

#Alpelisib#

4篇内容 | 771人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1605245, encodeId=affc16052454b, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, objectType=article, longId=216493, objectId=e168216493b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e168216493b8, replyNumber=0, likeNumber=58, createdTime=2021-09-01, rootId=0, userName=12498561m38(暂无昵称), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e168216493b8, moduleTitle=Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e168216493b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605244, encodeId=c03f1605244fe, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, objectType=article, longId=214659, objectId=4cc12146596f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cc12146596f, replyNumber=0, likeNumber=51, createdTime=2021-07-24, rootId=0, userName=12498561m38(暂无昵称), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cc12146596f, moduleTitle=Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4cc12146596f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605243, encodeId=078a160524305, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, objectType=article, longId=205897, objectId=fcad20589ed6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcad20589ed6, replyNumber=0, likeNumber=60, createdTime=2021-01-21, rootId=0, userName=12498561m38(暂无昵称), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcad20589ed6, moduleTitle=Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fcad20589ed6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1605242, encodeId=c94b1605242fc, content=<a href='/topic/show?id=fe7f2346eb' target=_blank style='color:#2F92EE;'>#Alpelisib#</a>, objectTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=59, createdTime=2019-08-07, rootId=0, userName=12498561m38(暂无昵称), userId=859419357438, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Alpelisib

2020-05-29

12498561m38(暂无昵称) (审核中...)

前往app查看评论内容

#Alpelisib#

Clin Cancer Res：口服选择性雌激素受体降解剂±Ribociclib或Alpelisib治疗ER+乳腺癌的疗效和安全性

2021-09-01

12498561m38(暂无昵称) (审核中...)

前往app查看评论内容

#Alpelisib#

Clin Cancer Res：Alpelisib联合曲妥珠单抗和LJM716治疗PIK3CA突变的HER2阳性转移性乳腺癌

2021-07-24

12498561m38(暂无昵称) (审核中...)

前往app查看评论内容

#Alpelisib#

Ann Oncol：Alpelisib+氟维司群治疗PIK3CA突变型HR+HER2-晚期乳腺癌的疗效

2021-01-21

12498561m38(暂无昵称) (审核中...)

前往app查看评论内容

#Alpelisib#

**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代

2019-08-07

科室
- - 订阅+
  - 更多科室
工具
服务